15
No role for
intraperitoneal
chemotherapy
No role for targeted
therapy
Basic setting
recommendations
Targeted therapy is
not recommended
in limited settings on
a routine basis for
patients with stage III
Patients referred
to be assessed for
appropriate evidence-
based intraperitoneal
chemotherapy,
following optimal
debulking, where
there are resources
and expertise to
manage toxicities
Assess patients
with stage III for
appropriate evidence-
based targeted
therapy, all patients
with high risk
features, and PS 0–2
